4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
XTL Biopharmaceuticals Ltd. (XTLB) operates in the Biotechnology industry and is headquartered in Herzliya, Israel with about 4 employees. Its market capitalization is roughly ₪20 million. In the fiscal year ended 2025-12-31, XTLB reported $0M in revenue and ($7M) in net income.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($1M) | ($1M) | ($1M) | ($1M) | — |
| Net Income | ($7M) | ($1M) | ($2M) | ($1M) | — |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Quarterly income statement | 2024-12-31 |
|---|---|
| Total Revenue | $0M |
| Gross Profit | $0M |
| Operating Income (EBIT) | ($1M) |
| Net Income | ($0M) |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $0M | $9M | $2M | $4M | — |
| Total Liabilities | $0M | $3M | $0M | $0M | — |
ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XTLB viewer.
This page in other languages: עברית
About TickerBase · Data methodology & sources · Privacy · Terms